R1 RCM (NASDAQ:RCM) Announces Earnings Results

R1 RCM (NASDAQ:RCMGet Rating) issued its earnings results on Monday. The healthcare provider reported $0.09 EPS for the quarter, missing analysts’ consensus estimates of $0.13 by ($0.04), Briefing.com reports. R1 RCM had a return on equity of 30.22% and a net margin of 6.59%. The firm had revenue of $385.70 million for the quarter, compared to analysts’ expectations of $384.18 million. During the same period last year, the firm earned ($2.37) earnings per share. R1 RCM’s revenue for the quarter was up 12.6% on a year-over-year basis. R1 RCM updated its FY 2022 guidance to EPS.

Shares of R1 RCM stock traded up $0.75 during trading hours on Tuesday, hitting $19.86. The company had a trading volume of 10,003 shares, compared to its average volume of 1,276,233. The company’s 50-day moving average is $25.25 and its two-hundred day moving average is $24.55. R1 RCM has a twelve month low of $18.71 and a twelve month high of $27.86. The company has a debt-to-equity ratio of 2.19, a current ratio of 1.43 and a quick ratio of 1.43. The company has a market cap of $5.53 billion, a P/E ratio of -8.89, a price-to-earnings-growth ratio of 2.46 and a beta of 0.86.

A number of equities research analysts have recently issued reports on RCM shares. Robert W. Baird boosted their price target on shares of R1 RCM from $29.00 to $32.00 in a research note on Thursday, March 3rd. Deutsche Bank Aktiengesellschaft reduced their price target on shares of R1 RCM from $30.00 to $28.00 in a research note on Tuesday. Zacks Investment Research raised shares of R1 RCM from a “hold” rating to a “buy” rating and set a $30.00 price target on the stock in a research note on Thursday, April 21st. Finally, Guggenheim began coverage on shares of R1 RCM in a research note on Wednesday, April 13th. They set a “neutral” rating on the stock. One analyst has rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to MarketBeat.com, R1 RCM currently has an average rating of “Buy” and an average target price of $29.25.

Several institutional investors have recently modified their holdings of the company. NewEdge Advisors LLC purchased a new position in shares of R1 RCM in the 4th quarter valued at about $204,000. Qtron Investments LLC acquired a new stake in shares of R1 RCM in the fourth quarter worth approximately $206,000. Janus Henderson Group PLC purchased a new position in R1 RCM in the third quarter valued at approximately $262,000. UBS Group AG raised its holdings in R1 RCM by 798.4% in the third quarter. UBS Group AG now owns 21,300 shares of the healthcare provider’s stock valued at $469,000 after buying an additional 18,929 shares during the period. Finally, LPL Financial LLC raised its holdings in R1 RCM by 3.3% in the third quarter. LPL Financial LLC now owns 40,236 shares of the healthcare provider’s stock valued at $886,000 after buying an additional 1,279 shares during the period. Institutional investors and hedge funds own 41.97% of the company’s stock.

R1 RCM Company Profile (Get Rating)

R1 RCM Inc provides revenue cycle management (RCM) for healthcare providers in the United States. The company offers end-to-end RCM services to manage their revenue cycle operations that encompass patient registration, insurance and benefit verification, medical treatment documentation and coding, bill preparation, and collections from patients and payers.

Recommended Stories

Earnings History for R1 RCM (NASDAQ:RCM)

Receive News & Ratings for R1 RCM Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for R1 RCM and related companies with MarketBeat.com's FREE daily email newsletter.